307 related articles for article (PubMed ID: 25207801)
1. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Wang Y; Cai H; Zhou G; Zhang Z; Liu X
J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
[TBL] [Abstract][Full Text] [Related]
4. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
7. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
8. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
10. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
[TBL] [Abstract][Full Text] [Related]
13. [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
Fang L; Zhao Y; Wang N; Yang Z; Huang H; Lin M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):871-6. PubMed ID: 26663068
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR
J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
[TBL] [Abstract][Full Text] [Related]
16. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Bhatt DL; Paré G; Eikelboom JW; Simonsen KL; Emison ES; Fox KA; Steg PG; Montalescot G; Bhakta N; Hacke W; Flather MD; Mak KH; Cacoub P; Creager MA; Berger PB; Steinhubl SR; Murugesan G; Mehta SR; Kottke-Marchant K; Lincoff AM; Topol EJ;
Eur Heart J; 2012 Sep; 33(17):2143-50. PubMed ID: 22450429
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
20. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
